Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study

Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure

“…The number of all-cause deaths, CV deaths, hospitalizations for HF, and all-cause deaths or HF hospitalizations are also provided. In the study by Lassus et al (17), among the 5,306 subjects included in the original study, only 728 had sST2 measured at admission; only this subgroup was considered for the present analysis. In the cohort of Sanders-van Wijk et al (21), only patients with AHF were included.…”

Evaluation of soluble ST2 as a novel cardiovascular biomarker in patients with acute myocardial infarction

“…[9][10][11][12] Increased concentrations of soluble ST-2 in patients with acute destabilized heart failure at their initial presentation indicate increased risk of future mortality. 13 Soluble ST-2 is independently associated with worsening heart failure.…”

Estimating systemic fibrosis by combining galectin-3 and ST2 provides powerful risk stratification value for patients after acute decompensated heart failure

“…www.cardiologyjournal.org Lassus et al [8] conducted an international collaborative study on patients hospitalized for acute HF, and showed that ST2 predicted 30-day and 1-year mortality. However, these data were analyzed from 12.7 ± 2.0** 13.7 ± 2.0 13.9 ± 1.7 13.6 ± 1.…”

“…ST2 is a protein of the interleukin-1 receptor family. Elevated serum levels of soluble ST2 are also associated with adverse outcomes in patients with acute decompensated or chronic HF [6][7][8].…”